Jurkat In Vivo Anti-Tumor Efficacy Assay (CAT#: ITS-1122-YF5774)

Jurkat

Human

The Jurkat cell line (originally called JM) was established in the mid-1970s from the peripheral blood of a 14-year-old boy with T cell leukemia. Different derivatives of the Jurkat cell line have been mutated to lack certain genes.

Acute Lymphoblastic Leukemia; ALL

Oncology

In Vivo Anti-Tumor Efficacy Assay

Jurkat-cell based In Vivo Anti-Tumor Efficacy Assay

After positive anti-tumor efficacy data is concluded using in vitro assays, we can start to initiate in vivo anti-tumor efficacy studies. Creative Biolabs offers a wide variety of PDX or CDX models to facilitate the efficacy studies. This assy will be used to evaluate the anti-tumor efficacy of your therapeutic candidates, such as small molecules, antibodies, CARTs or other biologics. Detailed group set up and other plans will be discussed according to your specific requirements.

Oncology In Vivo Assays